<DOC>
	<DOCNO>NCT00886808</DOCNO>
	<brief_summary>The goal study evaluate safety tolerability 4 different dos iCo-007 Intravitreal Injection patient diffuse diabetic macular edema .</brief_summary>
	<brief_title>Safety Study iCo-007 Intravitreal Injection Treat Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>1 . Men woman 18 year age old 2 . Confirmed diagnosis diabetes mellitus type I II ( , insulin noninsulin dependent ) 3 . Subjects moderate severe nonproliferative diabetic retinopathy ( NPDR ) , define ETDRS criterion , diffuse DME within 300 micron center macula study eye ( without cystoid change ) confirm FA . 4 . Retinal thickness must least 250 micron central subfield , show OCT 5 . Bestcorrected visual acuity 60 15 letter measure ETDRS chart ( approximately 20/63 20/500 Snellen chart ) 6 . Woman childbearing potential must pregnant lactating , must negative pregnancy test screening ( serum ) . Both men woman require practice adequate method birth control 7 . Able willing sign approve informed consent form return schedule study visit 1 . Subjects macular perimacular edema secondary etiology diabetes mellitus 2 . Subjects concurrent retinal disease condition study eye ( include condition require urgent PRP ) , glaucoma ( ocular hypertension ) , retinal vascular occlusion , exudative agerelated macular degeneration ( drusen permit ) , tear ( rip ) retinal pigment epithelium , vitelliformlike lesion outer retina ( e.g . pattern dystrophy basal laminar drusen ) , idiopathic parafoveal telangiectasis retinallesion anastomosis 3 . Subjects additional ocular disease condition could compromise treatment safety , visual acuity interfere assessment macular edema , ocular inflammation , amblyopia , anterior ischemic optic neuropathy , medium opacity , cataract 4 . Subjects diffuse DME severe capillary nonperfusion ( avascular zone diameter &gt; 1,000 micron ) 5 . Allergy fluorescein dye 6 . Subjects intraocular surgery , photocoagulation , intravitreal subfoveal injection , topical systemic steroid receive experimental treatment part another clinical trial within last 3 month study start ( case Anecortave within last 6 month , panretinal photocoagulation prior study start ) 7 . Subjects uncontrolled diabetes ( glycosylated hemoglobin Hb A1c &gt; 12 % ) 8 . Subjects systolic blood pressure high 180 mm Hg diastolic 100 mm Hg , without antihypertensive treatment 9 . Subjects congestive heart disease unstable cardiac condition 10 . Subjects clinically significantly impaired renal function ( serum creatinine &gt; 2.0 mg/dL ) and/or moderate severe hepatic impairment ( subject &gt; 2.5 time upper limit normal range aspartate transaminase [ AST ] , alanine transaminase [ ALT ] , total bilirubin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>DME , Diabetic Retinopathy , Diabetic Macular Edema</keyword>
</DOC>